Seaport Therapeutics, Inc.
- SPTX · Nasdaq
- Pharmaceutical Preparations
- Boston, MA
- CIK 0002042347
Updated from SEC filings through
Top things to know
Executives
- Daphne Zohar Co-Founder and Chief Executive Officer at Seaport Therapeutics 8-K, November 2, 2026
- Lauren White Chief Financial Officer Form 4, May 4, 2026
- Antony Loebel Chief Medical Officer Form 4, May 4, 2026
- Michael Cunyuan Chen Chief Scientific Officer Form 4, May 4, 2026
- Lana Gladstein General Counsel Form 4, May 4, 2026
What leadership is saying
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial”
Earnings press release (8-K Ex. 99.1), filed November 2, 2026
Seaport Therapeutics, Inc. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Boston, MA. It trades as SPTX on Nasdaq. Daphne Zohar is Co-Founder and Chief Executive Officer at Seaport Therapeutics.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Daphne Zohar Founder & CEO Seaport Therapeutics | Co-Founder and Chief Executive Officer at Seaport Therapeutics | 8-K, November 2, 2026 |
| Lauren White | Chief Financial Officer | Form 4, May 4, 2026 |
| Antony Loebel Innovative Pharmaceutical Executive I Extensive Clinical Development Expertise as Chief Medical Officer I Deep Neuropsychiatric R&D and Commercial Experience I | Chief Medical Officer | Form 4, May 4, 2026 |
| Michael Cunyuan Chen | Chief Scientific Officer | Form 4, May 4, 2026 |
| Lana Gladstein General Counsel | General Counsel | Form 4, May 4, 2026 |
Shares and governance
| Shares outstanding | 53.5 million (as of October 27, 2026) | 10-Q, November 2, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 2, 2026 |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| November 3, 2026 | Denice Torres Director | Buy | 5,000 | $99K | Form 4, November 4, 2026 |
| June 22, 2026 | Robert J. Hombach Director | Buy | 13,000 | $236K | Form 4, June 24, 2026 |
Recent 8-K events
- 8-K filed 2026-11-02
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-03
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-08
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-04
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
Frequently asked questions about Seaport Therapeutics, Inc.
- What does Seaport Therapeutics, Inc. do?
- Seaport Therapeutics, Inc. is classified by the SEC as Pharmaceutical Preparations (SIC 2834). It is based in Boston, MA.
- Who is the CEO of Seaport Therapeutics, Inc.?
- Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics, as named in a 8-K filed November 2, 2026.
- Who is the CFO of Seaport Therapeutics, Inc.?
- Lauren White, Chief Financial Officer, as named in a 4 filed May 4, 2026.
- Where is Seaport Therapeutics, Inc. headquartered?
- Boston, MA.
- What is Seaport Therapeutics, Inc.'s stock ticker?
- SPTX on Nasdaq.
- What industry is Seaport Therapeutics, Inc. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Seaport Therapeutics, Inc.'s website?
- seaporttx.com. Investor relations: https://investors.seaporttx.com/.
- When does Seaport Therapeutics, Inc. report earnings next?
- December 28, 2026. This is an estimate from past filing dates, not a confirmed date.
- Is Seaport Therapeutics, Inc. a public company?
- Yes. Seaport Therapeutics, Inc. files with the SEC under CIK 0002042347 and trades as SPTX.
- How many shares of Seaport Therapeutics, Inc. are outstanding?
- 53.5 million shares as of October 27, 2026, from its 10-Q filed November 2, 2026.
- How many business segments does Seaport Therapeutics, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 2, 2026.
- Have Seaport Therapeutics, Inc. insiders traded stock recently?
- Since June 22, 2026, officers and directors reported 0 open-market sales and 2 purchases worth about $335K on Forms 4 and 5. The most recent: Denice Torres (Director) bought 5,000 shares on November 3, 2026.